Management of Isolated DFS70 Antibodies in Postpartum Patients with Neuropathy

Diagnostic Approach

The American College of Rheumatology suggests that patients with isolated DFS70 antibodies at any titer, including 1:320, do not have systemic autoimmune rheumatic disease and require clinical monitoring only, unless additional autoantibodies or definitive clinical criteria for autoimmune disease develop 1
A comprehensive extractable nuclear antigen (ENA) panel is necessary to confirm that the DFS70 antibody is truly isolated, including tests for anti-Ro/SSA, anti-La/SSB, anti-Sm, anti-RNP, anti-Jo-1, and anti-dsDNA antibodies 1
Complement levels (C3, C4) should be assessed to evaluate for active autoimmune inflammation 2
A comprehensive metabolic panel and urinalysis should be performed to evaluate kidney and liver function and screen for proteinuria/hematuria suggesting lupus nephritis 1, 2

The European Neurological Society recommends a serum antiganglioside antibody panel for Guillain-Barré syndrome variants, a paraneoplastic antibody panel including ANNA-1 (anti-Hu) antibodies, and electrodiagnostic studies (nerve conduction studies and EMG) to characterize the neuropathy pattern 3
HbA1c, vitamin B12, vitamin B6, and folate levels should be checked to exclude reversible neuropathy causes 3
In patients with confirmed autoimmune disease, treatment decisions should be based on the specific autoimmune disease identified and clinical manifestations, and may include immunosuppressive therapy such as corticosteroids or IVIG 3, 4

Clinical monitoring every 6-12 months is recommended for patients with isolated DFS70 antibodies to monitor for development of autoimmune symptoms 1
Patients should be educated about warning symptoms of autoimmune disease, including persistent joint swelling, photosensitive rash, oral ulcers, pleuritic chest pain, unexplained fever, Raynaud's phenomenon, severe dry eyes/mouth, or progressive muscle weakness 1